From todays AFR, page-10

Raises an interesting point, looking ahead to the SARAH results. What if SIRT shows equivalent OS to sorafenib (could be interpreted as a failure on primary outcome) but demonstrates positive secondary outcomes such as lower costs, better QoL and fewer adverse effects? How will results be presented and how will the market react?

Many of us did well selling prior to the SIRFLOX announcement then buying back in. I'd rather hold through the SARAH announcement, but am wary of doing so in case we see a similar "dump then pump"!